Case Reports and Small Case Series
December 1999

Increase of Intraocular Pressure After Topical Administration of Prostaglandin Analogs

Author Affiliations

Copyright 1999 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1999

Arch Ophthalmol. 1999;117(12):1646-1647. doi:

Several prostaglandins have been demonstrated to reduce intraocular pressure (IOP) in normal, hypertensive, and glaucomatous eyes.13 Two different prostaglandin analogs are commercially available: unoprostone (Rescula; Ciba Vision Ophthalmics, Duluth, Ga) and latanoprost (Xalatan; Pharmacia Inc, Columbus, Ohio). We observed an inverse reaction after topical administration of both analogs.

Report of a Case

A 29-year-old woman had retinitis pigmentosa with typical ophthalmoscopic findings, a ring scotoma, and a flat electroretinogram. Juvenile glaucoma was diagnosed at the age of 12 years. Because of the characteristic malformation of the anterior segment it was classified as Rieger syndrome. The initial IOP at the time of glaucoma detection was 50 mm Hg. Both eyes underwent Elliot operation. The left eye required an additional cryocoagulation of the ciliary body. After these operations, the IOP of the right eye was between 8 and 14 mm Hg without further medication. The IOP of the left eye was below 21 mm Hg until the patient was 26 years old. The IOP then began to increase, and a second cryocoagulation was performed. After the second cryocoagulation, the IOP varied between 0 mm Hg (without therapy) and 41 mm Hg OS (with maximum tolerated medical therapy without prostaglandin analogs). At this time visual acuity was 6/30 OD and 6/12 OS.

After a 9-week period of IOP values between 30 and 34 mm Hg OS, we decided to try an additional treatment of 2 drops of unoprostone, 1 in the morning and 1 in the evening. In less than 24 hours, the IOP increased to 56 mm Hg, accompanied by corneal edema. After withdrawal of treatment with unoprostone, the IOP returned to 15 mm Hg. During the following weeks the IOP again ranged between 1 and 35 mm Hg. Five months after this trial with unoprostone, another prostaglandin analog, latanoprost, became available. At this time, the IOP again was about 30 mm Hg despite maximum tolerated medical therapy without prostaglandin analogs. As with unoprostone, the IOP immediately increased to 55 mm Hg after 2 drops of latanoprost. This increase of IOP was again accompanied by corneal edema and a decrease in visual acuity. With intravenous 20% mannitol, the IOP rapidly dropped to 20 mm Hg and later returned to 30 mm Hg.

We now decided to perform a stepwise diode laser cyclophotocoagulation. After 4 treatments with 2 burns each, the IOP ranged between 10 mm Hg and 20 mm Hg OS. However, 5 months after the last laser treatment, IOP decreased to 0 mm Hg and remained at this hypotonous level for 3 weeks. Treatment with systemic and local steroids failed to increase IOP, and visual acuity was only 6/120. This was the reason why we now tried to elevate IOP using prostaglandin analogs. In fact, after 2 drops of unoprostone, IOP increased to 55 mm Hg within 36 hours and visual acuity increased to 6/20 (Figure 1).

Image not available

Time course of intraocular pressure (IOP) for both eyes. Arrows indicate application of prostaglandin derivates or cyclophotocoagulation only of the left eye.

There were no signs of acute anterior segment inflammation after the prostaglandin applications. A marked atrophy of the ciliary body was observed with high-resolution ultrasound biomicroscopy.


In the literature, we could not find any other reports of serious, reproducible IOP increase after unoprostone or latanoprost administration. These prostaglandin analogs are known to be safe and effective in reducing IOP.13 It is presumed that they facilitate the uveoscleral outflow, whereas trabecular outflow may be slightly impaired.4 One might speculate that, in our patient, uveoscleral outflow was considerably alterated by the disease itself (Rieger syndrome and retinitis pigmentosa) or by the cryoprocedures. The atrophy of the ciliary body supports this theory. Because of these alterations, prostaglandins perhaps could not further improve uveoscleral outflow. Thus, the slight impairment of trabecular outflow could have caused the IOP increase.

Back to top
Article Information

Corresponding author: Thomas Ness, MD, Universitäts-Augenklinik Freiburg, Killianstr. 5, D-79106 Freiburg, Germany.

Alm  AStjernschantz  J Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. Ophthalmology. 1995;1021743- 1752Article
Fujimori  CYamabayashi  SHosoda  M  et al.  The clinical evaluation of UF-021, a new prostaglandin-related compound, in low-tension glaucoma. Nippon Ganka Gakkai Zasshi. 1993;971231- 1235
Ziai  NDolan  JWKacere  RDBrubaker  RF The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;1111351- 1358Article
Gabelt  BTKaufman  PL The effect of prostaglandin F2 alpha on trabecular outflow facility in cynomolgus monkeys. Exp Eye Res. 1990;5187- 91Article